Medications for X-Linked Hypophosphatemia
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in X-Linked Hypophosphatemia.
Found 1 Approved Drug for X-Linked Hypophosphatemia
Crysvita
Generic Name
Burosumab
Crysvita
Generic Name
Burosumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: April 18, 2018
CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for: The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances